Parathyroid Hormone Market Size Projected To Increase From $2.8 Billion To $4.39 Billion During The Forecast Period
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Parathyroid Hormone Market Forecast Highlighting Growth From $2.8 Billion To $4.39 Billion
The market for parathyroid hormone has experienced rapid expansion in recent years, with projections indicating an increase from $2.51 billion in 2025 to $2.8 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.5%. This historical growth has been driven by factors such as the restricted supply of recombinant parathyroid hormone, limited patient awareness of the disease, a continued dependence on conventional vitamin D therapy, the expansion of hospital and clinic facilities, and a rising incidence of post-surgical parathyroid complications.
The market for parathyroid hormone is projected to experience significant expansion in the coming years, reaching a valuation of $4.4 billion by 2030 with a compound annual growth rate (CAGR) of 11.9%. This growth during the forecast period is driven by factors such as the development of advanced parathyroid hormone analogues, the increasing adoption of personalized medicine strategies, the growth of hospitals and specialty clinics, the integration of digital tools for patient monitoring, and enhanced government and healthcare initiatives targeting hypocalcemia and hypoparathyroidism. Key trends shaping the forecast period include a higher prevalence of hypocalcemia and hypoparathyroidism, the expanding use of recombinant parathyroid hormone therapies, the rise of tailored parathyroid hormone analogues for individual treatment, the expansion of hospital- and clinic-based parathyroid care programs, and a stronger focus on post-surgical management alongside vitamin D supplementation.
Download A Free Sample Report For Comprehensive Market Insights:
Parathyroid Hormone Market Growth Factors Supporting Long-Term Expansion
The growing number of older adults is anticipated to drive expansion in the parathyroid hormone market in the coming years. This demographic, consisting of individuals aged 65 and above, often faces age-associated health issues and requires tailored medical attention. Factors such as longer life expectancy, improved healthcare services, and reduced birth rates contribute to this shift, leading to a larger share of elderly people within the population. Parathyroid hormone plays a critical role for seniors by managing calcium levels and bone metabolism, thereby lowering the risk of osteoporosis and fractures that frequently affect this age group. For example, in January 2024, the Population Reference Bureau, a U.S.-based nonprofit, reported that the number of Americans aged 65 and older is forecasted to rise from 58 million in 2022 to 82 million by 2050—a 47% increase. Additionally, the proportion of this segment in the overall population is expected to climb from 17% to 23% over the same timeframe. Consequently, the rising elderly population is fueling growth in the parathyroid hormone market.
Parathyroid Hormone Market Segment Outlook: Which Categories Are Expanding The Fastest?
The parathyroid hormone market covered in this report is segmented –
1) By Disease Type: Hypocalcemia, Hypoparathyroidism
2) By Product Type: Recombinant Parathyroid Hormone, Parathyroid Hormone Analogues
3) By End-User: Hospitals, Clinics, Other End-Users
Subsegments:
1) By Hypocalcemia: Pseudohypoparathyroidism, Vitamin D Deficiency
2) By Hypoparathyroidism: Post-Surgical Hypoparathyroidism, Idiopathic Hypoparathyroidism
Parathyroid Hormone Market Industry Trends Shaping Future Revenue Growth
Major players in the parathyroid hormone market are concentrating on the creation of biosimilars for parathyroid-based therapies, including prodrugs of parathyroid hormone (PTH), aimed at broadening the range of available treatments. These prodrugs, which are inactive forms that convert into active PTH once administered, facilitate a delayed release mechanism that delivers stable therapeutic effects for managing calcium balance and bone health. A notable example is the FDA’s approval in August 2024 of YORVIPATH (palopegteriparatide) by Ascendis Pharma A/S, a biopharmaceutical company headquartered in Denmark, marking it as the exclusive therapy for adult hypoparathyroidism. Administered once daily, this prodrug ensures uninterrupted PTH exposure, benefiting approximately 70,000 to 90,000 individuals in the United States. Patient support is offered by Ascendis Pharma through the ascendis signature access program (A.S.A.P.), yet it necessitates regular serum calcium monitoring to prevent hypercalcemia or hypocalcemia.
Parathyroid Hormone Market Key Companies And Competitive Benchmarking
Major companies operating in the parathyroid hormone market are Pfizer Inc., Eli Lilly and Company, Radius Health Inc., Ascendis Pharma, Entera Bio Ltd., Extend Biosciences Inc., Gedeon Richter Plc., Abbott Laboratories, Amgen Inc., Merck & Co. Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Alcon Laboratories Inc., Bayer Healthcare, AstraZeneca PLC, Biocon, Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals, Jubilant Life Sciences, Lupin Limited, Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Wockhardt, Cipla Limited
Access The Complete Parathyroid Hormone Market Report:
Parathyroid Hormone Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the parathyroid hormone market in 2025. The Middle East is expected to be the fastest-growing region in the global parathyroid hormone market share during the forecast period. The regions covered in the parathyroid hormone market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
